Gene Editing's Unwritten Rulebook: Safety Before Speed The latest cautionary tales from the gene editing frontier are sobering reminders that rewriting human DNA remains a developing science.
Stanford University's Karoly Nikolich, a prominent figure in brain science commercialization, has expressed concerns about the maturity of gene editing techniques for human studies.
Nikolich's comments follow two tragic cases: a young girl who died after receiving experimental treatment for her rare genetic disorder and a boy who succumbed to complications from CRISPR therapy in Shanghai.